C.R. Bard, Inc. (NYSE:BCR) insider Jim C. Beasley sold 3,395 shares of C.R. Bard stock in a transaction dated Thursday, December 14th. The stock was sold at an average price of $332.00, for a total transaction of $1,127,140.00. Following the completion of the transaction, the insider now owns 25,630 shares of the company’s stock, valued at approximately $8,509,160. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

C.R. Bard, Inc. (NYSE:BCR) opened at $333.83 on Wednesday. The company has a market cap of $24,330.00, a P/E ratio of 28.89, a P/E/G ratio of 2.56 and a beta of 0.52. C.R. Bard, Inc. has a 12 month low of $218.72 and a 12 month high of $337.73. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings data on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. C.R. Bard’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.64 earnings per share. equities analysts forecast that C.R. Bard, Inc. will post 11.89 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be paid a dividend of $0.26 per share. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $1.04 annualized dividend and a yield of 0.31%. C.R. Bard’s dividend payout ratio is currently 13.70%.

A number of large investors have recently modified their holdings of BCR. Schwab Charles Investment Management Inc. grew its stake in C.R. Bard by 3.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 240,591 shares of the medical instruments supplier’s stock valued at $76,054,000 after acquiring an additional 8,697 shares in the last quarter. Alps Advisors Inc. grew its stake in C.R. Bard by 0.3% during the second quarter. Alps Advisors Inc. now owns 1,921 shares of the medical instruments supplier’s stock valued at $607,000 after acquiring an additional 5 shares in the last quarter. Gamco Investors INC. ET AL purchased a new position in C.R. Bard during the second quarter valued at approximately $9,987,000. Ballentine Partners LLC purchased a new position in C.R. Bard during the second quarter valued at approximately $387,000. Finally, Nippon Life Insurance Co. purchased a new position in C.R. Bard in the 2nd quarter worth approximately $1,070,000. 79.11% of the stock is owned by institutional investors.

Several equities analysts have recently weighed in on the stock. ValuEngine downgraded shares of C.R. Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Cowen reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Friday, November 3rd. Barclays lifted their target price on shares of C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. Finally, Jefferies Group reiterated a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research note on Thursday, September 14th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the company’s stock. C.R. Bard currently has a consensus rating of “Hold” and a consensus target price of $303.50.

TRADEMARK VIOLATION WARNING: “Jim C. Beasley Sells 3,395 Shares of C.R. Bard, Inc. (BCR) Stock” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/jim-c-beasley-sells-3395-shares-of-c-r-bard-inc-bcr-stock/1773914.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard and related companies with MarketBeat.com's FREE daily email newsletter.